Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Double Dose of Alpha 1-antitrypsin Augmentation Therapy on Lung Inflammation.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01669421
Recruitment Status : Completed
First Posted : August 21, 2012
Results First Posted : May 8, 2019
Last Update Posted : May 8, 2019
Sponsor:
Collaborator:
CSL Behring
Information provided by (Responsible Party):
Michael Campos, MD, University of Miami

Brief Summary:

The current treatment of individuals with alpha-1 antitrypsin deficiency (AATD) who develop lung disease (COPD) is the administration of intravenous purified alpha-1 antitrypsin (augmentation therapy) at a fixed dose of 60 mg/kg per week. This dose aims at increasing the deficient AAT serum levels just above a predetermined "safety threshold" of 11 uM. However, normal levels of AAT are between 25-50 uM.

AAT has shown not only to inhibit lung proteases such as neutrophil elastase, but also to modulate inflammation. Given that many subjects with AATD who receive augmentation therapy still have significant lung disease and inflammation, this study will evaluate whether doubling the dose to 120 mg/kg/week has an effect in decreasing lung inflammation.

Only the dosing of 60 mg/kg /week has received FDA approval. FDA has granted an IND number to this study to test the higher dose of 120 mg/kg/week.

The study will evaluate systemic (serum) and pulmonary (bronchoscopy samples)markers of inflammation in 3 phases: standard dose (4 weeks), double dose (4 weeks) and standard dose (4 weeks).


Condition or disease Intervention/treatment Phase
Alpha 1 Antitrypsin Deficiency Drug: Alpha-1 Antitrypsin (human) Phase 2

Detailed Description:

This is a pilot study to test the effect of double dose augmentation therapy with Zemaira (CSL Behring) on lung inflammation, compared with standard doses of 60 mg/kg/week.

Our hypothesis is that some patients with AATD receiving augmentation therapy at the standard dose of 60 mg/kg/week continue to have a significant lung inflammation that may lead to detrimental clinical consequences. This inflammation can be further reduced with higher AAT dosing.

The study will enroll 20 subjects with AATD and COPD already receiving augmentation therapy with any brand at standard doses for at least a month. For inclusion and exclusion criteria see below.

Protocol:

The study will take place over approximately 12 weeks: a month receiving Zemaira at standard dose (60 mg/kg/week), a month at double dose (120 mg/kg/week) and a month at standard dose (60 mg/kg/week). The infusions at standard doses will be done at home and infusions with higher doses will be provided at the study site.

the study involves scheduled blood draws for clinical labs and serum for research samples. At the end of each phase a bronchoscopy will be performed (3 in total) to obtain research samples (lung lavage, brushings and endobronchial biopsies).

The first bronchoscopy after receiving 4 weeks of standard augmentation therapy will assess the "residual" inflammation that may be present despite augmentation therapy. The second bronchoscopy after double dose augmentation therapy phase will be to assess changes (decreases) in inflammatory markers. The third bronchoscopy after resuming standard dosing is to assess if inflammation returned to baseline levels (required for proof of concept).

There will be approximately 9 visits to the study clinic. This study does not include placebo (no active drug) treatment. Besides blood draws and bronchoscopy, the study will include questionnaires and lung function testing.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of a Higher Dose of Alpha-1 Antitrypsin Augmentation Therapy on Lung Inflammation in Subjects With Alpha-1 Antitrypsin Deficiency.
Study Start Date : July 2012
Actual Primary Completion Date : May 2016
Actual Study Completion Date : May 2016


Arm Intervention/treatment
Experimental: Alpha-1 Antitrypsin (human) standard dose baseline
Alpha-1 Antitrypsin (human) 60 mg per kg per week for 4 weeks. Study week 4
Drug: Alpha-1 Antitrypsin (human)
Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Other Names:
  • Zemaira
  • Alpha-1 proteinase inhibitor (human)

Experimental: Alpha-1 Antitrypsin (human) Double dose
Alpha-1 Antitrypsin (human) 120 mg/kg per week for 4 weeks. Study week 8
Drug: Alpha-1 Antitrypsin (human)
Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Other Names:
  • Zemaira
  • Alpha-1 proteinase inhibitor (human)

Experimental: Alpha-1 Antitrypsin (human) standard dose
4 weeks on A1PI at 60 mg/kg per week after the other 2 phases. Collected@ study week 12
Drug: Alpha-1 Antitrypsin (human)
Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
Other Names:
  • Zemaira
  • Alpha-1 proteinase inhibitor (human)




Primary Outcome Measures :
  1. Changes in Inflammatory Biomarkers in Bronchoalveolar Lavage Fluid [ Time Frame: Between baseline (week 4), double dose A1PI (week 8) and again standard dose (week 12) ]

    Assess the variations in the levels of several cytokines and inflammatory biomarkers in BAL after changing A1PI dosing.

    Measures were done using the bead technology.



Secondary Outcome Measures :
  1. Change in Inflammatory Biomarkers in Serum Samples [ Time Frame: Between baseline (week 4), double dose A1PI (week 8) and again standard dose (week 12) ]
    Assess the variations in the levels of cytokines and inflammatory biomarkers using the bead technology.

  2. Number of Adverse Events Reported [ Time Frame: From Week 1 to week 12 ]

Other Outcome Measures:
  1. Elastin Degradation in BAL [ Time Frame: Week 4 vs Week 8 vs Week 12 ]
    Desmosine/isodesmosine measured using mass spectometry.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Males or Females aged between 18 and 75 years.
  • Diagnosis of AATD, based on documentation of "at-risk" genotypes such as Pi ZZ, SZ or Znull OR documentation of a pre-therapy AAT level < 11 µM.
  • Evidence of COPD (emphysema or airflow obstruction) with FEV1 < 80%
  • Receiving standard dose of augmentation therapy (with any commercial formulation) for at least 1 month at the dose of 60 mg/kg/week.
  • At least ONE of the following criteria of disease severity:

    • 2 or more acute exacerbations or 1 hospitalization due to respiratory symptoms in the past 12 months. Definition of exacerbations: the use of antibiotics and a course of steroids to treat a flare of pulmonary symptoms, regardless if the subject required emergency room care or hospital admission. The diagnosis of the acute exacerbation will be obtained by direct history obtained from the patient and confirmed by the PI. Attempts should be made to have documentation from the patient's treating physicians, although not required for study entry.
    • St. George Respiratory Questionnaire (SGRQ) total score ≥ 60.
    • Chronic bronchitis: daily or almost daily sputum expectoration at least 3 months of the year for at least 2 consecutive years. The diagnosis of chronic bronchitis will be obtained by direct history obtained from the patient and confirmed by the PI. Attempts should be made to have documentation from the patient's treating physicians, although not required for study entry.
    • Documented FEV1 decline of at least ≥ 60 ml/year for 2 consecutive years while receiving augmentation therapy

Exclusion Criteria:

- Patients unsuitable to have a bronchoscopy due to poor clinical condition as judged by the PI. In general we will exclude subjects with hypoxemia, coagulopathy or FEV1 below 40% predicted.

Note: Subjects with FEV1 values below 40% predicted may be included and reassessed after optimization of therapy. Final determination to include the patient if deemed suitable for the procedure will be determined by the PI before first planned bronchoscopy (regardless of FEV1 value).

  • Patients participating in other clinical trials.
  • Use of chronic antibiotics or oral steroids
  • Continues to smoke
  • Inability to sign informed consent
  • Pregnancy or willing to become pregnant
  • Known IgA deficiency (we will include only patients already receiving augmentation therapy so it will be unlikely to encounter this exclusion criteria)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01669421


Locations
Layout table for location information
United States, Florida
Division of Pulmonary and Critical Care, Human Reseach, U of Miami
Miami, Florida, United States, 33136
Sponsors and Collaborators
Michael Campos, MD
CSL Behring
Investigators
Layout table for investigator information
Principal Investigator: Michael A Campos, MD University of Miami

Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Michael Campos, MD, Associate Professor, University of Miami
ClinicalTrials.gov Identifier: NCT01669421     History of Changes
Other Study ID Numbers: 20100844
First Posted: August 21, 2012    Key Record Dates
Results First Posted: May 8, 2019
Last Update Posted: May 8, 2019
Last Verified: April 2019
Keywords provided by Michael Campos, MD, University of Miami:
Alpha 1
Additional relevant MeSH terms:
Layout table for MeSH terms
Alpha 1-Antitrypsin Deficiency
Pneumonia
Inflammation
Pathologic Processes
Liver Diseases
Digestive System Diseases
Lung Diseases
Respiratory Tract Diseases
Genetic Diseases, Inborn
Subcutaneous Emphysema
Emphysema
Respiratory Tract Infections
Alpha 1-Antitrypsin
Protein C Inhibitor
Trypsin Inhibitors
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action